Randomized phase III study of gemcitabine-cisplatin versus etoposide- cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 12-18

  Cardenal, Felipe ^a   Paz Lopez Cabrerizo M ^a   Antón, Antonio ^a   Alberola, Vicent ^a   Massuti, Bartomeu ^a   Carrato, Alfredo ^a   Barneto, Isidoro ^a   Lomas, María ^a   García, Margarita ^a   Lianes, Pilar ^a   Montalar, Joaquín ^a   Vadell, Catalina ^a   González Larriba, José Luis ^a   Nguyen, Binh ^a   Artal, Angel ^a   Rosell MD, Rafael ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0345148774     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.12     Document Type: Article

References (23)

1. Hansen HH: Is there a role for chemotherapy of non-small-cell lung cancer? Ann Oncol 6:79-82, 1995 (suppl 1)
2. Grilli R, Oxman AD, Jullian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
3. Souquet PS, Chauvin F, Boisse JP, et al: Polychemotherapy in advanced non-small-cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
4. Marino P, Pampallona S, Preatoni A, et al: Chemotherapy vs. supportive care in advanced non-small-cell lung cancer: Results of a meta-analysis of the literature. Chest 106:861-865, 1994
5. Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
6. [American Society of Clinical Oncology] Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15:2996-3018, 1997
7. Anderson H, Lund B, Bach F, et al: Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
8. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
9. Gatzemeier U, Shepherd FA, Le Chevalier T: Activity of gemcitabine in patients with non-small-cell lung cancer: A multicenter expanded phase II study. Eur J Cancer 32A:243-248, 1996
10. Manegold C, Bergman B, Chemaissani A, et al: Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomized phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8:525-529, 1997
11. Perng R-P, Chen Y-M, Ming-Liu J, et al: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097-2102, 1997
12. Peters GD, Ruiz van Haperen VWT, Bergman AM, et al: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23:16-24, 1996 (suppl 10)
13. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15:744-749, 1997
14. Crinò L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
15. Steward WP, Dunlop DJ, Dabouis G, et al: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer: Preliminary results. Semin Oncol 23:43-47, 1996 (suppl 10)
16. Einhorn LH: Phase II trial of gemcitabine plus cisplatin in non-small-cell lung cancer: A Hoosier Oncology Group Study. Semin Oncol 24:24-26, 1997 (suppl 8)
17. Anton A, Artal A, Carrato A, et al: Gemcitabine plus cisplatin in advanced NSCLC: Final phase II results. Proc Am Soc Clin Oncol 16:461, 1997 (abstr 1656)
18. Splinter TA: Chemotherapy in advanced non-small-cell lung cancer. Eur J Cancer 26:1093-1099, 1990
19. Aaranson K, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
20. Bergman B, Aarounson NK, Ahmezdai S, et al: The EORTC QLQLC-13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994
21. Shepherd FA, Cormier Y, Burkes R, et al: Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer. Semin Oncol 24:27-30, 1977 (suppl 8)
22. Buyse M, Piedbois P: On the relationship between response to treatment and survival time. Stat Med 15:2797-2812, 1996
23. [American Society of Clinical Oncology] Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996